BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38155973)

  • 1. Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma.
    Belle CJ; Lonie JM; Brosda S; Barbour AP
    Front Immunol; 2023; 14():1330635. PubMed ID: 38155973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
    Lonie JM; Brosda S; Bonazzi VF; Aoude LG; Patel K; Brown I; Sharma S; Lampe G; Addala V; Koufariotis LT; Wood S; Waddell N; Dolcetti R; Barbour AP
    Front Immunol; 2023; 14():1220129. PubMed ID: 37965317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High CD8
    Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
    Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma.
    Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J
    World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma.
    Melo AM; O'Brien AM; Phelan JJ; Kennedy SA; Wood NAW; Veerapen N; Besra GS; Clarke NE; Foley EK; Ravi A; MacCarthy F; O'Toole D; Ravi N; Reynolds JV; Conroy MJ; Hogan AE; O'Sullivan J; Dunne MR
    Front Immunol; 2019; 10():1580. PubMed ID: 31354725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma.
    McShane R; Arya S; Stewart AJ; Caie PD; Bates M
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188598. PubMed ID: 34332022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches.
    Lonie JM; Barbour AP; Dolcetti R
    Cancer Treat Rev; 2021 Jul; 98():102219. PubMed ID: 33993033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
    Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
    Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.
    Davern M; O' Brien RM; McGrath J; Donlon NE; Melo AM; Buckley CE; Sheppard AD; Reynolds JV; Lynam-Lennon N; Maher SG; Lysaght J
    Sci Rep; 2022 Feb; 12(1):3259. PubMed ID: 35228614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
    Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
    Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours.
    Davern M; Fitzgerald MC; Buckley CE; Heeran AB; Donlon NE; McGrath J; O' Connell F; Deshpande MR; Hayes C; MacDonald J; Sheppard AD; Reynolds JV; Maher SG; Lynam-Lennon N; Murphy B; Lysaght J
    Transl Oncol; 2022 May; 19():101381. PubMed ID: 35245832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
    Noble F; Mellows T; McCormick Matthews LH; Bateman AC; Harris S; Underwood TJ; Byrne JP; Bailey IS; Sharland DM; Kelly JJ; Primrose JN; Sahota SS; Bateman AR; Thomas GJ; Ottensmeier CH
    Cancer Immunol Immunother; 2016 Jun; 65(6):651-62. PubMed ID: 27020682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling.
    Donlon NE; Davern M; Sheppard A; Power R; O'Connell F; Heeran AB; King R; Hayes C; Bhardwaj A; Phelan JJ; Dunne MR; Ravi N; Donohoe CL; O'Sullivan J; Reynolds JV; Lysaght J
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
    Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
    Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
    Oner G; Broeckx G; Van Berckelaer C; Zwaenepoel K; Altintas S; Canturk Z; Tjalma W; Berneman Z; Peeters M; Pauwels P; van Dam PA
    Cancer Med; 2023 Sep; 12(17):17901-17913. PubMed ID: 37553911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; Habash M; Sheppard AD; MacLean M; Dunne MR; Moore J; Temperley H; Conroy MJ; Butler C; Bhardwaj A; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
    Cancer Immunol Immunother; 2023 Jan; 72(1):55-71. PubMed ID: 35708739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.